title: Aggressive Chordomas: Clinical Outcome of 13 Patients.
abstract: The authors reviewed the files of all patients with chordomas who were admitted and treated at their institutions from 1975 to 2012. Patients were categorized by early local recurrence and metastasis. Aggressive clinical behavior was defined as local recurrence and metastasis within 24 months of diagnosis and adequate treatment (wide en bloc resection with microscopically negative tumor margins). According to these criteria, 13 patients (14.3%) had aggressive chordomas, including 7 men and 6 women, with mean age of 54 years (range, 37-65 years) at diagnosis and treatment. All patients had preoperative tumor biopsy, followed by resection with partial (7 patients) or total sacrectomy (6 patients). In all cases, biopsy and histologic analysis of resected tumor specimens showed conventional chordomas. Resection margins were wide (grossly negative) in 6 patients and wide contaminated in 7 patients. Mean maximum tumor diameter was 11.8 cm (range, 5-21 cm). Mean follow-up was 43 months (range, 8-131 months). Rates of local recurrence, metastasis, and death were evaluated. At the last follow-up, all patients had local recurrence at a mean of 13 months (range, 5-22 months). Histologic examination of recurrent tumors showed a dedifferentiated chordoma with a fibrosarcoma component in 2 patients and no histologic change in the remaining patients. In addition, 8 patients had metastases at a mean of 13 months (range, 4-24 months) and died of their disease. All histologic findings of metastatic lesions were similar to those of primary tumors. Early diagnosis of aggressive tumors requires close follow-up of patients with chordomas. Metastasis is common, with resultant poor survival. [Orthopedics. 2017; 40(2):e248-e254.].
authors.forename: Andreas F
authors.initials: AF
authors.lastname: Mavrogenis
authors.forename: Andrea
authors.initials: A
authors.lastname: Angelini
authors.forename: Georgios N
authors.initials: GN
authors.lastname: Panagopoulos
authors.forename: Elisa
authors.initials: E
authors.lastname: Pala
authors.forename: Teresa
authors.initials: T
authors.lastname: Calabrò
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Igoumenou
authors.forename: Galatia
authors.initials: G
authors.lastname: Katzouraki
authors.forename: Panayiotis D
authors.initials: PD
authors.lastname: Megaloikonomos
authors.forename: Spyros G
authors.initials: SG
authors.lastname: Pneumaticos
authors.forename: Panayiotis J
authors.initials: PJ
authors.lastname: Papagelopoulos
authors.forename: Pietro
authors.initials: P
authors.lastname: Ruggieri
mesh_terms: D000328:Adult; D000368:Aged; D002817:Chordoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D019637:Orthopedic Procedures; D011379:Prognosis; D013125:Spinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome